Odyssey Therapeutics Q2 FY26 net loss widens to $52.8 million - ODTX News | RalliesOdyssey Therapeutics Q2 FY26 net loss widens to $52.8 million
O
ODTX• Pipeline updates
- OD-001 Phase 2a data were accepted for an October oral presentation.
- Phase 2b monotherapy and Phase 2a vedolizumab-combination trials are expected to start in 2H 2026.
Adjusted loss and cash position
- Non-GAAP adjusted net loss was $38.4 million, excluding $8.7 million of non-cash fair-value charges and $5.7 million of stock-based compensation.
- Cash, cash equivalents and marketable securities totaled $433.1 million at June 30, expected to fund operations into the second half of 2028.
Quarterly loss widens as R&D spending rises
- Odyssey Therapeutics posted a GAAP net loss of $52.8 million in Q2 2026, widening from a $41.2 million loss a year earlier.
- R&D expense rose to $36.2 million from $30.2 million, while G&A expense fell to $10.5 million from $13.2 million.
CME
•
